This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Kraft Heinz's (KHC) Operating Model & Pricing Efforts Solid
by Zacks Equity Research
Kraft Heinz (KHC) is committed to its operating model, which incorporates five key elements. Also, solid pricing initiatives are yielding.
Nu Skin (NUS) Shines on Solid Sales Leaders & Customer Network
by Zacks Equity Research
Nu Skin Enterprises (NUS) has been benefiting from its efforts to empower sales leaders and strengthen the customer base.
Campbell Soup (CPB) Focuses on Saving Efforts Amid High Costs
by Zacks Equity Research
Campbell Soup (CPB) has been gaining on its strategic priorities as well as saving efforts amid rising cost inflation.
Flowers Foods (FLO) Is Poised on Core Priorities, Solid Pricing
by Zacks Equity Research
Flowers Foods (FLO) has been gaining on its strategic priorities, such as developing its team, concentrating on brands, prioritizing margins and looking out for prudent mergers and acquisitions.
Is Medifast (MED) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Medifast (MED) a New Buy Stock
by Zacks Equity Research
Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are These Consumer Staples Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Helen of Troy (HELE) Q3 Earnings Beat, Fiscal 2022 View Up
by Zacks Equity Research
Helen of Troy (HELE) Q3 reflects strong consumer and retailer demand for the Housewares and Beauty segments aiding core sales and earnings.
Tyson Foods (TSN) Up More Than 20% in 6 Months: Will it Stay?
by Zacks Equity Research
Tyson Foods (TSN) is focused on higher protein production to cater to higher demand for protein-packed food. Also, robust demand in its retail core business lines is a driver.
Conagra (CAG) Q2 Earnings Lag Estimates, Sales Increase Y/Y
by Zacks Equity Research
Conagra Brands' (CAG) second-quarter fiscal 2022 results reflect lower earnings due to cost inflation. Management ups organic net sales view but keeps earnings per share guidance intact.
Lamb Weston (LW) Q2 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Lamb Weston's (LW) second-quarter fiscal 2022 results reflect year-over-year sales growth on increased sales volumes and price/mix. However, earnings declined year over year.
Post Holdings (POST) Gains on Solid BellRing Brands & Buyouts
by Zacks Equity Research
Post Holdings (POST) is expanding its portfolio through strategic acquisitions. The company's BellRing Brands unit is gaining from strength in Premier Protein and Dymatize banners.
Mondelez's (MDLZ) Chipita Addition Boosts Snacks Portfolio
by Zacks Equity Research
Mondelez (MDLZ) is making prudent buyouts to drive growth. The buyout of Chipita strengthens MDLZ's snacking category.
Colgate (CL) Well Poised on Growth Strategies Amid Cost Woes
by Zacks Equity Research
Despite raw material cost inflation, Colgate's (CL) robust innovation and expansion plans are likely to drive growth in the long term.
Is Medifast (MED) Stock Outpacing Its Consumer Staples Peers This Year?
by Zacks Equity Research
Here is how Medifast (MED) and SunOpta (STKL) have performed compared to their sector so far this year.
Medifast (MED) Gains on OPTAVIA Strength, SG&A Costs Rise
by Zacks Equity Research
Medifast (MED) has been gaining on strength of its OPTAVIA lifestyle solution and coaching support system, which was a major driver in the third quarter.
Should Value Investors Pick Medifast (MED) Stock Now?
by Vedika Agarwal
Is Medifast (MED) a great pick from the value investor's perspective right now? Read on to know more.
Medifast (MED) Raises View on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Medifast's (MED) third-quarter 2021 results reflect stellar earnings and revenues, courtesy of continued strength in OPTAVIA. Management raises earnings per share and revenue guidance for 2021.
Medifast (MED) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medifast (MED) delivered earnings and revenue surprises of 21.92% and 1.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Factors to Consider as Medifast (MED) Gears Up for Q3 Earnings
by Zacks Equity Research
Medifast's (MED) third-quarter results are likely to reflect gains from the OPTAVIA lifestyle solution and coaching support system, though high costs are a concern.
Medifast (MED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medifast's (MED) OPTAVIA System a Key Driver, SG&A Costs High
by Zacks Equity Research
Medifast (MED) has long been gaining on the strength of its OPTAVIA lifestyle solution and coaching support system, while rising SG&A costs are a worry.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Kimberly-Clark (KMB) on Track With Saving Efforts Amid Cost Woes
by Zacks Equity Research
Kimberly-Clark (KMB) is committed toward saving actions, which are likely to help the company amid the rising cost challenges.
McCormick's (MKC) Q3 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
McCormick's (MKC) third-quarter fiscal 2021 results reflect the impact of higher sales driven by growth in the Flavor Solutions and Consumer units. Management updates fiscal 2021 sales view upward.